Compare Amphastar Pharmaceuticals Inc (AMPH) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Procter & Gamble Co — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.31 (market cap $863.95M), while Procter & Gamble Co trades at $145.26 (market cap $340.39B). The key difference: Procter & Gamble Co is far larger — about 394× Amphastar Pharmaceuticals Inc's market cap, and Procter & Gamble Co pays a 2.97% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | PG | |
|---|---|---|
Market Cap | $863.95M | $340.39B |
Sector | Health | Consumer Staples |
52-Week High | $30.81 | $167.18 |
52-Week Low | $16.87 | $138.10 |
Enterprise Value | $1.26B | $366.23B |
Volume | — | 6,423,436 |
Dividend Yield | — | 2.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Procter & Gamble (PG) trades at $144.88, down 0.61% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a net income margin of 18.44% and consistent earnings beats in recent quarters, including Q2 2026 EPS of $1.43 versus $1.41 expected. Revenue reached $84.28 billion in 2025, with a gross profit margin of 50.18%. Recent news highlights PG's dividend reliability and supply chain enhancements, though valuation multiples like a P/E of 22.12 remain elevated compared to peers.
The outlook is cautiously optimistic, supported by analyst consensus favoring Buy ratings (52.83%) and a price target of $161.20, implying potential upside. Risks include premium valuation pressure and soft demand concerns. PG's stable cash flow and 69-year dividend growth history offer defensive appeal in volatile markets, but investors should monitor execution against modest revenue growth projections.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
